Experts are rapidly examining retatrutide, a promising treatment created by Eli Lilly, as a possible step in weight management. Different than many existing approaches, retatrutide is a double -action agonist targeting equally GLP-1 and GIP, chemicals that impact satiety and blood sugar regulation